Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL – Get Rating)'s stock price gapped up prior to trading on Thursday . The stock had previously closed at $18.11, but opened at $18.71. Zentalis Pharmaceuticals shares last traded at $18.71, with a volume of 1 shares.
Wall Street Analysts Forecast Growth
A number of research firms have recently commented on ZNTL. SVB Leerink lowered their target price on Zentalis Pharmaceuticals from $42.00 to $27.00 and set an "outperform" rating for the company in a research report on Thursday, November 10th. Wedbush dropped their price objective on shares of Zentalis Pharmaceuticals from $51.00 to $32.00 and set an "outperform" rating for the company in a research note on Monday, November 14th. Wells Fargo & Company decreased their target price on shares of Zentalis Pharmaceuticals from $52.00 to $46.00 in a research report on Monday, November 14th. Oppenheimer dropped their price target on Zentalis Pharmaceuticals from $80.00 to $50.00 and set an "outperform" rating for the company in a research report on Thursday, November 10th. Finally, Morgan Stanley reduced their price objective on Zentalis Pharmaceuticals from $60.00 to $55.00 and set an "overweight" rating on the stock in a research note on Friday, November 11th. Nine research analysts have rated the stock with a buy rating, According to MarketBeat, the company has an average rating of "Buy" and an average price target of $46.56.
Get
Zentalis Pharmaceuticals alerts:
Zentalis Pharmaceuticals Stock Performance
The stock has a fifty day moving average of $21.14 and a 200-day moving average of $24.48. The company has a market cap of $1.15 billion, a PE ratio of -4.27 and a beta of 1.80.
Insider Activity
In related news, President Cam Gallagher sold 12,500 shares of the firm's stock in a transaction dated Wednesday, October 5th. The shares were sold at an average price of $22.32, for a total value of $279,000.00. Following the transaction, the president now owns 431,885 shares of the company's stock, valued at approximately $9,639,673.20. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at
this link. Over the last ninety days, insiders sold 50,000 shares of company stock valued at $1,153,375. 19.90% of the stock is currently owned by company insiders.
Institutional Inflows and Outflows
Several hedge funds and other institutional investors have recently bought and sold shares of the company. JPMorgan Chase & Co. lifted its holdings in shares of Zentalis Pharmaceuticals by 284.2% in the 1st quarter. JPMorgan Chase & Co. now owns 105,579 shares of the company's stock worth $4,871,000 after buying an additional 78,102 shares during the period. US Bancorp DE grew its holdings in Zentalis Pharmaceuticals by 378.9% during the 1st quarter. US Bancorp DE now owns 1,451 shares of the company's stock worth $67,000 after acquiring an additional 1,148 shares in the last quarter. MetLife Investment Management LLC increased its position in Zentalis Pharmaceuticals by 57.0% during the 1st quarter. MetLife Investment Management LLC now owns 19,665 shares of the company's stock valued at $907,000 after purchasing an additional 7,139 shares during the period. Rhumbline Advisers raised its holdings in shares of Zentalis Pharmaceuticals by 7.0% in the 1st quarter. Rhumbline Advisers now owns 37,923 shares of the company's stock valued at $1,750,000 after purchasing an additional 2,475 shares in the last quarter. Finally, Integral Health Asset Management LLC lifted its position in shares of Zentalis Pharmaceuticals by 79.2% in the 1st quarter. Integral Health Asset Management LLC now owns 215,000 shares of the company's stock worth $9,920,000 after purchasing an additional 95,000 shares during the period.
About Zentalis Pharmaceuticals
(Get Rating)
Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; Phase 1/2 clinical trial for the treatment of advanced solid tumors as a monotherapy and in an ongoing Phase 1b clinical trial in combination with chemotherapy in patients with platinum resistant ovarian cancer; and Phase 2 monotherapy trial for a tumor agnostic, predictive biomarker.
Read More
- Get a free copy of the StockNews.com research report on Zentalis Pharmaceuticals (ZNTL)
- MarketBeat: Week in Review 12/26 – 12/30
- The Dogs Of Tech: It's Time For A Bite Of These Stocks
- Does This Acquisition Make Microsoft a Bear Market Buy?
- Is Kintara Therapeutics A Hidden Gem?
- Should You Warm up to Generac Stock for the Winter?
Receive News & Ratings for Zentalis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zentalis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
